{"id":35709,"date":"2026-07-15T17:07:00","date_gmt":"2026-07-15T11:37:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35709"},"modified":"2026-07-15T15:07:44","modified_gmt":"2026-07-15T09:37:44","slug":"rise-of-targeted-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics","title":{"rendered":"The Rise of Targeted Therapeutics in Modern Healthcare"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a5b1c11c0039\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a5b1c11c0039\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics\/#Key_Benefits_of_Targeted_Therapeutics\" >Key Benefits of Targeted Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics\/#Common_Challenges_with_Targeted_Therapeutics\" >Common Challenges with Targeted Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics\/#Role_of_AI_in_Targeted_Therapeutics\" >Role of AI in Targeted Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics\/#Future_of_Targeted_Therapeutics\" >Future of Targeted Therapeutics<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>For most of medical history, treating disease meant casting a wide net. Chemotherapy attacked every fast-dividing cell it could find, healthy or cancerous. Broad-spectrum drugs treated symptoms without ever asking why a particular patient&#8217;s biology behaved the way it did. That era is ending. Targeted therapeutics, treatments engineered to lock onto the specific genes, proteins, or signaling pathways that drive a disease, have moved from experimental promise to clinical mainstay in barely two decades. Monoclonal antibodies like <strong>rituximab and trastuzumab<\/strong> rewired treatment for lymphoma and HER2-positive breast cancer. Oral kinase inhibitors now push response rates above <strong>90%<\/strong> in biomarker-positive chronic myeloid leukemia patients, a number that would have sounded implausible for a &#8220;targeted&#8221; drug class a generation ago.<\/p>\n\n\n\n<p>The numbers back up the shift. DelveInsight estimates the <a href=\"https:\/\/www.delveinsight.com\/report-store\/targeted-therapeutics-market\">global targeted therapeutics market<\/a> at roughly <strong>$78.5 billion<\/strong> in 2025, on pace to increase to over <strong>$124 billion<\/strong> by 2034, a compound annual growth rate near <strong>5%<\/strong>. Monoclonal antibodies alone account for close to two-thirds of that revenue. In the United States, more than <strong>2.1 million<\/strong> new cancer cases are projected in 2026, a patient population that increasingly expects, and receives, treatment matched to their tumor&#8217;s genetic fingerprint rather than a generic protocol.<\/p>\n\n\n\n<p>This is precision medicine made commercial. And it&#8217;s not confined to oncology anymore: targeted biologics are reshaping how the industry approaches autoimmune disease, rare genetic disorders, and inflammatory conditions. What follows is a closer look at why targeted therapeutics are winning, where they still struggle, how artificial intelligence is accelerating the next wave, and what the competitive landscape looks like heading into the back half of this decade.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-benefits-of-targeted-therapeutics\"><span class=\"ez-toc-section\" id=\"Key_Benefits_of_Targeted_Therapeutics\"><\/span><strong>Key Benefits of Targeted Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The single biggest advantage of targeted therapeutics is precision. Rather than flooding the body with a compound and hoping it does more good than harm, these drugs are designed to bind to a specific molecular marker, a mutated gene, an overexpressed receptor, an aberrant signaling protein, that is present on diseased cells but largely absent from healthy ones. Trastuzumab&#8217;s affinity for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/her2-positive-market-forecast\">HER2 receptor<\/a>, or a tyrosine kinase inhibitor&#8217;s grip on a mutated ATP-binding site, means the drug does its job in a narrower, more predictable lane. That narrower lane translates directly into fewer off-target effects and a materially better quality-of-life profile for patients who might otherwise face the blunt-force toxicity of conventional chemotherapy or systemic immunosuppression.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"493\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics-1024x493.webp\" alt=\"Major-Advantages-of-Targeted-Therapeutics\" class=\"wp-image-35714\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics-1024x493.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics-300x145.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics-150x72.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics-768x370.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics-1536x740.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Advantages-of-Targeted-Therapeutics.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>That precision also changes the economics of clinical success. Because targeted therapies are matched to biomarker-positive populations through companion diagnostics, physicians can predict, with far greater confidence, which patients are likely to respond before treatment even begins. This reduces the trial-and-error cycle that has historically defined oncology and chronic disease management, where patients might cycle through several ineffective regimens before finding one that works. Faster identification of the right drug for the right patient shortens time-to-benefit and reduces the cumulative burden of ineffective treatment.<\/p>\n\n\n\n<p>Targeted therapeutics have also expanded what is treatable in the first place. Diseases once considered nearly undruggable because they lacked an obvious broad-spectrum intervention, certain rare mutations, specific fusion proteins, and narrowly defined molecular subtypes of cancer, have become addressable once researchers could identify and design a molecule against the exact driver of pathology. <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugate-adc-market\">Antibody-drug conjugates<\/a> and bispecific antibodies are pushing this further, delivering cytotoxic payloads or engaging immune cells with a specificity that simply wasn&#8217;t achievable with earlier drug classes.<\/p>\n\n\n\n<p>Finally, there&#8217;s a durability advantage. Because targeted agents interfere with mechanisms that are often central to a disease&#8217;s survival, not just symptoms, many produce deeper and more sustained responses than symptomatic treatment alone. This is part of why payers and health systems, despite the high price tags often attached to targeted biologics, increasingly view them as a net value proposition: better outcomes, fewer hospitalizations from treatment toxicity, and, in some cases, genuine long-term disease control.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-common-challenges-with-targeted-therapeutics\"><span class=\"ez-toc-section\" id=\"Common_Challenges_with_Targeted_Therapeutics\"><\/span><strong>Common Challenges with Targeted Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The precision that makes targeted therapeutics powerful is also their biggest constraint. A drug designed against a specific biomarker simply doesn&#8217;t work for the patient who doesn&#8217;t have that biomarker. This makes robust, accessible, and affordable companion diagnostics a prerequisite rather than an afterthought, and in many health systems, especially outside high-resource markets, genomic and molecular testing infrastructure still lags behind the pace of drug approvals. A therapy can be scientifically brilliant and clinically inaccessible if the diagnostic needed to identify eligible patients isn&#8217;t routinely available.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"320\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics-1024x320.webp\" alt=\"Major-Challenges-of-Targeted-Therapeutics\" class=\"wp-image-35715\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics-1024x320.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics-300x94.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics-150x47.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics-768x240.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics-1536x480.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Major-Challenges-of-Targeted-Therapeutics.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Cost remains a persistent friction point. <a href=\"https:\/\/www.delveinsight.com\/report-store\/monoclonal-antibody-market\">Monoclonal antibodies<\/a>, antibody-drug conjugates, and other biologic-based targeted therapies are expensive to manufacture, and that expense flows through to list prices that can run into hundreds of thousands of dollars annually per patient. Policy responses are already reshaping the landscape. In the US, Medicare&#8217;s Inflation Reduction Act price negotiations have begun lowering costs for select high-volume drugs, and similar pricing pressure is building in other major markets. Balancing innovation incentives against affordability and access will likely remain one of the defining tensions of this decade.<\/p>\n\n\n\n<p>Resistance is another hard problem. Tumors and other disease processes are not static; under the selective pressure of a targeted drug, cancer cells in particular can evolve new mutations that evade the very pathway being blocked. This is why so much current R&amp;D investment goes toward combination regimens, next-generation inhibitors designed to overcome known resistance mutations, and sequencing strategies that anticipate how a disease might adapt rather than treating a single snapshot of its biology.<\/p>\n\n\n\n<p>Manufacturing and regulatory complexity round out the list. Biologics require sophisticated, tightly controlled production processes that are far less forgiving than small-molecule manufacturing, and scaling that production globally, while maintaining consistency batch to batch, is a genuine operational challenge. On the regulatory side, agencies are still refining frameworks for narrowly indicated, biomarker-defined approvals, adaptive trial designs, and increasingly, for therapies developed with heavy AI involvement, where questions about model transparency and validation are only beginning to be formalized.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-role-of-ai-in-targeted-therapeutics\"><span class=\"ez-toc-section\" id=\"Role_of_AI_in_Targeted_Therapeutics\"><\/span><strong>Role of AI in Targeted Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Artificial intelligence has moved from a peripheral research tool to a structural part of how targeted therapeutics get discovered, designed, and deployed. At the target identification stage, machine learning models trained on genomic, transcriptomic, and proteomic datasets can flag disease-driving genes and proteins far faster than traditional wet-lab screening, helping researchers prioritize which biological targets are actually worth pursuing before committing years of lab work to them.<\/p>\n\n\n\n<p>Molecule design has arguably seen the most visible transformation. Protein structure prediction tools in the AlphaFold lineage, along with generative chemistry platforms, now let researchers model how a candidate molecule will physically interact with its target before synthesizing a single compound. Companies built entirely around this capability, from established players to a new wave of AI-native biotechs, are pushing candidates into clinical trials with development timelines that would have been difficult to imagine a decade ago, though the industry is still gathering long-term data on whether AI-designed molecules translate into higher approval rates, not just faster early-stage progress.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"327\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline-1024x327.webp\" alt=\"AI-targeted-Therapeutics-Pipeline\" class=\"wp-image-35716\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline-1024x327.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline-300x96.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline-150x48.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline-768x246.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline-1536x491.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/AI-targeted-Therapeutics-Pipeline.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>AI is equally influential downstream. Multi-omic data fusion models help stratify patients into biomarker-defined subgroups with more precision than manual analysis allows, directly supporting the patient-matching that targeted therapy depends on. In clinical trials, AI-assisted analysis of <a href=\"https:\/\/www.delveinsight.com\/blog\/role-of-electronic-health-records-in-modern-healthcare\">electronic health records<\/a> and claims data is helping sponsors identify eligible patients and optimal trial sites faster, addressing one of the industry&#8217;s most persistent bottlenecks: trial recruitment timelines that routinely stretch into years. Post-launch, AI-driven real-world evidence analysis is helping surface new indications, safety signals, and biomarker correlations from real clinical use, turning ongoing patient data into a feedback loop that continuously refines how these therapies are used.<\/p>\n\n\n\n<p>None of this replaces the clinical and regulatory rigor targeted therapeutics require. But it compresses timelines at nearly every stage of the pipeline, and as more AI-discovered candidates move through Phase II and Phase III trials over the next few years, the industry will get a clearer answer to the question that matters most: does AI-assisted discovery ultimately produce better medicines, not just faster ones.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-future-of-targeted-therapeutics\"><span class=\"ez-toc-section\" id=\"Future_of_Targeted_Therapeutics\"><\/span><strong>Future of Targeted Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current market landscape suggests targeted therapeutics are still in the early-middle innings of their growth curve, not the late stage. Monoclonal antibodies continue to hold the largest share of therapy-type revenue, while antibody-drug conjugates, bispecific antibodies, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/rna-therapeutics-market\">RNA-targeted therapeutics<\/a> are the fastest-growing categories layered on top of that base. North America currently leads on regional market share, underpinned by dense biotech infrastructure and sustained NCI-backed research funding, while Asia-Pacific is widely expected to post the fastest regional growth rate through the early 2030s, fueled by expanding ADC manufacturing capacity and streamlining regulatory pathways in markets like China and India.<\/p>\n\n\n\n<p>The competitive landscape spans both legacy pharma giants and a fast-growing cohort of AI-native challengers. Established leaders, <strong>Roche\/Genentech, Pfizer, AstraZeneca, Amgen, Bristol Myers Squibb, AbbVie, Johnson &amp; Johnson, Gilead Sciences, Novartis, and Merck<\/strong>, continue to anchor the market through deep oncology and immunology pipelines, extensive manufacturing scale, and aggressive M&amp;A. Eli Lilly&#8217;s 2026 acquisition of Kelonia Therapeutics to strengthen its in vivo CAR-T pipeline is a representative example of how quickly big pharma is moving to acquire next-generation targeted modalities rather than build them from scratch.&nbsp;<\/p>\n\n\n\n<p>Alongside these incumbents, a new class of companies, <strong>Recursion Pharmaceuticals, Isomorphic Labs, Insilico Medicine, Exscientia, Tempus AI, Xaira Therapeutics<\/strong>, and others, are increasingly influential not as drug companies in the traditional sense, but as platform and infrastructure players whose AI capabilities are being licensed, partnered with, and in some cases acquired by the industry&#8217;s largest names.<\/p>\n\n\n\n<p>Looking ahead, several forces will likely define the next phase of growth: broader <a href=\"https:\/\/www.delveinsight.com\/blog\/companion-diagnostics-in-healthcare\">adoption of companion diagnostics<\/a> as a standard part of first-line treatment decisions rather than a specialty add-on; continued expansion of targeted approaches beyond oncology into autoimmune, cardiometabolic, and rare genetic disease; regulatory frameworks that catch up to AI-assisted discovery and adaptive, biomarker-driven trial designs; and mounting pricing pressure that will push the industry toward value-based contracting rather than list-price-driven commercialization. None of this diminishes the underlying trajectory. Targeted therapeutics represent the clearest example yet of medicine moving from population-level treatment toward individualized biology, and the market, the science, and the competitive landscape are all converging around that same direction of travel.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/targeted-therapeutics-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook-1024x194.webp\" alt=\"Targeted Therapeutics Market Outlook\" class=\"wp-image-35713\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Targeted-Therapeutics-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>For most of medical history, treating disease meant casting a wide net. Chemotherapy attacked every fast-dividing cell it could find, healthy or cancerous. Broad-spectrum drugs treated symptoms without ever asking why a particular patient&#8217;s biology behaved the way it did. That era is ending. Targeted therapeutics, treatments engineered to lock onto the specific genes, proteins, [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35711,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[78,1900,20719,291,403,23047],"industry":[17226],"therapeutic_areas":[17228],"class_list":["post-35709","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-antibody-drug-conjugates","tag-companion-diagnostics","tag-electronic-health-records","tag-her2","tag-monoclonal-antibodies","tag-targeted-therapeutics","industry-medical-devices","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Targeted Therapeutics: A Smarter Way to Treat Disease<\/title>\n<meta name=\"description\" content=\"The current market landscape suggests targeted therapeutics are still in the early-middle innings of their growth curve, not the late stage.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targeted Therapeutics: A Smarter Way to Treat Disease\" \/>\n<meta property=\"og:description\" content=\"The current market landscape suggests targeted therapeutics are still in the early-middle innings of their growth curve, not the late stage.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T11:37:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Targeted Therapeutics: A Smarter Way to Treat Disease","description":"The current market landscape suggests targeted therapeutics are still in the early-middle innings of their growth curve, not the late stage.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics","og_locale":"en_US","og_type":"article","og_title":"Targeted Therapeutics: A Smarter Way to Treat Disease","og_description":"The current market landscape suggests targeted therapeutics are still in the early-middle innings of their growth curve, not the late stage.","og_url":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-07-15T11:37:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"The Rise of Targeted Therapeutics in Modern Healthcare","datePublished":"2026-07-15T11:37:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics"},"wordCount":1687,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics.webp","keywords":["Antibody-Drug Conjugates","Companion diagnostics","Electronic Health Records","Her2","monoclonal antibodies","Targeted Therapeutics"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics","name":"Targeted Therapeutics: A Smarter Way to Treat Disease","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics.webp","datePublished":"2026-07-15T11:37:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The current market landscape suggests targeted therapeutics are still in the early-middle innings of their growth curve, not the late stage.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/rise-of-targeted-therapeutics#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics.webp","width":466,"height":284,"caption":"rise-of-targeted-therapeutics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/rise-of-targeted-therapeutics-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Companion diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Electronic Health Records<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Her2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">monoclonal antibodies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Targeted Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">Companion diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Electronic Health Records<\/span>","<span class=\"advgb-post-tax-term\">Her2<\/span>","<span class=\"advgb-post-tax-term\">monoclonal antibodies<\/span>","<span class=\"advgb-post-tax-term\">Targeted Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 days ago","modified":"Updated 3 days ago"},"absolute_dates":{"created":"Posted on Jul 15, 2026","modified":"Updated on Jul 15, 2026"},"absolute_dates_time":{"created":"Posted on Jul 15, 2026 5:07 pm","modified":"Updated on Jul 15, 2026 3:07 pm"},"featured_img_caption":"rise-of-targeted-therapeutics","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35709"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35709\/revisions"}],"predecessor-version":[{"id":35717,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35709\/revisions\/35717"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35711"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35709"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35709"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}